MOLECULAR GENETIC MARKERS AS PREDICTORS OF SUPERFICIAL BLADDER CANCER

• Main Authors: A. Yu. Babayan, S. V. Bashkatov, O. B. Karyakin, A. A. Teplov, M. P. Golovashchenko, V. V. Shkarupo, D. V. Zaletayev, M. V. Nemtsova
• Format: Article
• Language: Russian
• Published: ABV-press 2014-08-01
• Series: Onkourologiâ
• Subjects: superficial bladder cancer; prognosis; molecular genetic markers
• Online Access: http://oncourology.abvpress.ru/index.php/oncur/article/view/255

A system of clinical and morphological criteria is currently used to determine the pattern of superficial bladder cancer (SBC). However, this system does not completely reflect the clinical potential of SBC and needs additional markers. The purpose of this study was to search for and evaluate molecular genetic disorders as additional markers of the course of SBC. The diagnostic panel included the deletion of the loci 3р14, 9р21, 9q34, 17р13 (ТР53), mutations of exon 7 of the FGFR3 gene, and hypermethylation of the promoter regions of the RASSF1, RARB, p16, p14, CDH1 genes. The study was made on 108 matched samples (tumor/peripheral blood) obtained from patients with SBC. The deletions of the loci 3р14, 9р21 and anomalous methylation of the RARb and p16 genes are markers of the worse course of SBC while FGFR3 gene mutation is a marker of better prognosis. In the context of estimation of the relapsing potential of a primary tumor, the 9p21 locus deletion is a marker associated with recurrence within the first year after malignancy resection. The group of molecular genetic markers determined by the authors for poor prognosis in combination with classical clinical and morphological criteria will specify the pattern of the course of the disease and its prognosis.